Advance your immunotherapy drug development with patient-derived organoids
Despite the success of immuno-oncology (IO) agents in combating certain types of cancer, immunotherapies are effective in only a small percentage of patients. A major challenge that impedes the development of new immunotherapies is the lack of preclinical models that preserve patient-specific tumor antigens and recapitulate the complex interaction between the human immune system and tumor cells.
HUB Organoids are directly derived from patient tumor resections or biopsies and can be used to generate clinically-relevant data that allow you to identify the best IO candidates from a large library of compounds, evaluate the efficacy and potency of your IO agent, investigate the mechanism of action, and, refine drug combination strategies to optimize the overall performance of your immunotherapeutic.
Our organoid-based immuno-oncology platform offers a unique solution that is:
- Patient-relevant thanks to faithfully recapitulating patient-specific tumor antigens
- Representative of patient population diversity by maintaining both intra- and inter-tumor heterogeneity that is lost in conventional in vitro models
- Easily expandable and stable 3D in vitro culture for large-scale screenings
- Fast as compared to any in vivo systems
- Amenable to autologous co-cultures with patient-derived autologous as well as non-autologous immune cells
- Accountable for off-target and off-tumor toxicities as it allows the testing of clinical candidates in both patient-derived tumors and matched normal organoids
